【摘要】 目的:探讨尿激酶院前溶栓治疗对急性心肌梗死患者心血管事件再发风险的影响。方法:选取本院心内科急性心肌梗死患者89例,观察组45例,采用院前溶栓治疗,对照组44例,采用院后溶栓治疗,采用酶联免疫吸附试验(ELISA)方法测定氨基末端脑钠肽前体(NT-pro BNP)、超敏C反应蛋白(hs-CRP)水平,比较两组冠脉再通率、NT-pro BNP和hs-CRP水平的差异。结果:观察组冠脉再通率明显高于对照组(P<0.05),治疗前,两组NT-pro BNP、hs-CRP水平比较差异无统计学意义(P>0.05),治疗后,两组上述指标均呈下降倾向,其中观察组NTpro BNP、hs-CRP水平明显低于对照组,两组比较差异具有统计学意义(P<0.05),且心绞痛再发、AMI再发和心力衰竭等心血管事件发生率明显降低,两组比较差异具有统计学意义(P<0.05)。结论:尿激酶院前溶栓治疗有助于改善急性心肌梗死患者冠脉再通,降低心血管事件再发风险,其可能与院前溶栓显著抑制NT-pro BNP、hs-CRP水平有关。更多还原

【Abstract】 Objective:To investigate the effect of cardiovascular events recurrence risk of urokinase pre-hospital thrombolytic therapy for acute myocardial infarction.Method:89 cases of acute myocardial infarction from Cardiology department were selected,pre-hospital thrombolysis therapy were as observation group,post-hospital thrombolytic treatment were as control group,NT-pro BNP,hs-CRP were detected by ELISA,the difference of coronary recanalization rate,NT-pro BNP and hsCRP levels between groups were compared.Result:The coronary artery recanalization rate of observation group was significantly higher than control group(P<0.05),before treatment,NT-pro BNP and hs-CRP level had not statistically significant difference between two groups(P>0.05),after treatment, all above indexes showed elevated tendency, which observation group were significantly lower than control group,with significant differences(P<0.05),cardiovascular events(angina recurrence,recurrent AMI and heart failure occurring)were significantly reduced,the difference between two groups was significant(P<0.05).Conclusion:Urokinase pre-hospital thrombolytic therapy helps improving coronary reperfusion and reducing cardiovascular events recurrent risk for acute myocardial infarction,it may be related to significantly inhibit NT-pro BNP,hs-CRP level.更多还原